

23<sup>rd</sup> January, 2021

<p><b>BSE Limited</b> Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001</p> <p><b><u>Scrip Code: 532300</u></b></p>	<p><b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051</p> <p><b><u>NSE Symbol: WOCKPHARMA</u></b></p>
--	--

Dear Sir/Madam,

We wish to enclose herewith the newspaper publication of the Notice of the Board Meeting to be held on 29<sup>th</sup> January, 2021 published in Business Standard (English) and Navshakti (Marathi) on 23<sup>rd</sup> January, 2021

Kindly take the same on record.

Thanking you,

For **Wockhardt Limited**



**Gajanand Sahu**  
**Company Secretary**

Encl : As above



# Luxury cars in top gear

With over 50 new launches this year, super-premium marques are taking a calculated bet on the Indian market that touched a decadal low in 2020

SHALLY SETH MOHILE  
Mumbai, 22 January

After touching a decadal low in 2020, luxury carmakers in India are back with a vengeance. The top three firms — Mercedes-Benz India, BMW India and Audi India that account for the lion's share of the segment — have lined up over 50 new model launches as they seek to recoup previous years' loss in volumes.

Thanks to the pandemic, sales of super-premium models (those priced over ₹30 lakh) in 2020 were almost pushed back to 2010 levels (see table). The year-on-year decline, too, was a whopping 40 per cent. Even as the recovery in the Covid-19 pandemic remains patchy and high taxation weighs in on buyer sentiment, companies are optimistic that the new launches will rekindle excitement in a segment that accounts for less than 2 per cent of India's passenger vehicle market. This pales in comparison with China where the share of the luxury car segment is 13 per cent and the US where such high-end models account for 10 per cent of the car market.

A high taxation structure, among other factors, has limited the expansion of the segment. Even in its best year — 2018 — it was far away from the 50,000-mark. Automobiles attract a Goods and Services Tax rate of 28 per cent. The additional cess on top of the duty makes the effective tax on luxury cars as high as 50 per cent. India also levies more than 110 per cent import duty on fully built cars.

To be sure, luxury carmakers are riding high on the month-on-month uptick in sales and improving macroeconomic cues. They believe a strong preference for personal mobility will also hold them in good stead. They expect new launches and last year's low base to help them drive double digit growth in the current year.

Take BMW India, for instance. The second largest luxury car maker in the pecking order plans to launch at least 25 new models (includes BMW Motorrad bikes, BMW and Mini brands) in 2021 and expects to end the year in high teens, said Vikram Pahwa, president BMW Group India, on the sidelines of the launch of the BMW 3 Series Gran Limousine.

A week ago, luxury car market leader Mercedes-Benz India said it will launch 15 new models in 2021. "This will be the highest number of models we have ever launched in India in a single year and will include facelifts of existing models and completely new models. We expect a strong recovery in the next two years and a 40 per cent year-on-year (y-o-y) growth in each year," Martin Schwenk, MD & CEO, told



## A SELECTIVE TASTE FOR LUXURY

Sales figures

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
■ Audi	3,232	4,664	9,054	10,076	10,886	11,176	7,684	7,837	6,463	4,594	1,693
■ BMW+Mini	6,511	9,828	9,416	7,583	7,334	6,833	7,447	8,993	11,105	9,641	6,604
■ Mercedes	5,808	7,430	7,070	8,903	10,206	12,745	13,471	15,088	15,538	13,786	7,893
■ JLR	248	1,776	2,443	2,805	2,732	2,717	3,125	3,995	4,596	3,900	2,800
<b>Total</b>	<b>15,799</b>	<b>25,709</b>	<b>27,983</b>	<b>29,367</b>	<b>31,158</b>	<b>33,471</b>	<b>31,697</b>	<b>35,913</b>	<b>37,702</b>	<b>31,921</b>	<b>18,990</b>

Source: IHS Markit/Industry sources

Business Standard in a recent interview.

At the start of the year, Balbir Singh Dhillon, head — Audi India, said the Volkswagen group firm would bring almost a dozen new models to India to fill the product gaps in its line-up. Among the luxury car majors, Audi has seen a steady drop in volumes from a high in 2015.

So what explains this optimism among luxury car makers given that job losses are yet to be reversed significantly? And does this strategy make sense?

At least part of the reason for the expectations of pick-up could be that, as Kavan Mukhtyar, Partner and Leader, Automotive at PwC, pointed out, the fundamentals of the economy haven't changed and it is expected to bounce back by FY22 as the vaccine programme expands.

Also, despite the high rate of taxation on luxury cars, "many global manufacturers are looking at the Indian market as an important one, and they want to take growth to the next level," he added. That partly explains the aggressive pace of launches.

Although this market is unlikely to see

brisk growth given that people are still recovering from job losses, salary cuts and business closures, new launches will bring back the excitement to some degree.

But Puneet Gupta, director — IHS Markit, believes the road ahead for these companies may not be smooth. "New launches alone cannot guarantee success," he said.

Besides the tax burden, he pointed out that premium car makers also have competition from mass market players that are launching new models in the premium segment at attractive prices. "Why would someone consider an entry-level model in the luxury car segment if they can get a premium SUV at the same price," he asked.

Meanwhile, frequent policy changes and taxation have also stymied the growth of the segment, he said. Schwenk, along with his peers, has been lobbying for a reduction in cess and rationalisation in import duty in the upcoming Budget. But with the government urgently in need of funds to stimulate the economy, it is unlikely to risk the political optics of cutting taxes for something like luxury cars. So these accelerated launch programmes may well find themselves in the slow lane soon.

# Templeton's closures leave a bad taste

ANDY MUKHERJEE  
22 January

The courtroom drama over shutting down six of Franklin Templeton's local Indian mutual funds will soon come to an end, but the denouement shines an unkind light on how the country is running its capital markets.

Almost 97 per cent of unitholders have voted in favour of winding up the plans, which the US fund house abruptly put into suspended animation during a nationwide Covid-19 lockdown last April. But what choice did investors really have?

As the website Moneylife reported, the Yes button in the e-voting form promised "a potential to realise fair value." The option marked No threatened a "distress sale of assets." In deference to behavioural economist Richard Thaler's Nudge theory, the alternatives were colour-coded green and red, respectively.

More than the nudge, however, it's the winks that can do long-term damage. Unitholders were scared into voting, as Moneylife editor and shareholder activist Sucheta Dalal put it, "without any information about the extent of loss, the culpability of fund managers, the failure of trustees, what investors can hope to get back and the payment schedule." It was the regulator's job to insist on these details, and the failure to do so won't inspire confidence.



For years now, faith in the integrity of India's markets has haemorrhaged, with everyone from rating firms to auditors, fund managers and trustees putting their own commercial interests above — and often against — those of the investing public.

The Templeton episode was yet another opportunity to start setting things right. By the looks of it, the chance has been blown.

When I first wrote about the now-failed mutual funds in late 2018, it was in the context of their bet on then-Yes Bank Chief Executive Officer Rana Kapoor's family investment vehicle. Nominally, the exposure was via zero-coupon bonds, but they didn't trade and in most cases were held in their entirety by Templeton. Worse, this was symptomatic of an industry that had come around to stuffing risky, illiquid securities in short-maturity debt mutual fund portfolios to make

their yields look attractive.

By then, the game of artificial performance enhancement was already in extra time. The sudden bankruptcy of the IL&FS Group, a large infrastructure financier, in September

2018 had paralysed credit markets. The Securities and Exchange Board needed to urgently rein in errant debt funds. It remained asleep at the switch even as Yes Bank collapsed and had to be bailed out, Kapoor was taken into judicial custody, and Templeton pleaded for higher borrowing limits to meet redemption pressure, a request SEBI perplexingly granted.

Then the pandemic came, and the Templeton funds went into limbo with \$4 billion in assets under management. They have since received a little under \$2 billion from maturing investments, prepayments and coupons. One has outstanding borrowings. The remaining five,

which have turned cash positive, are in a position to return \$1.26 billion, "subject to fund-running expenses."

Franklin said in April that it won't take management fees from plans that are being shuttered, and regulations do allow it to charge costs. SEBI must still question the fairness of making unitholders pay for a forced haircut.

Beyond that, there must be consequences. Deepak Shenoy, CEO of Bengaluru-based wealth manager Capitalmind, suggests taking away two years' worth of Templeton's past fees as fines — and paying it out to distressed investors. But how interested is SEBI in really wielding the regulatory stick? Not very, if a \$2 million penalty on Mukesh Ambani in a 13-year-old case of alleged manipulative trading is anything to go by. India's richest man has a net worth of \$79.5 billion.

After being lambasted by the judiciary for acting as a "silent spectator," the regulator is still opposed to making Franklin's audit report public, according to proceedings this week in India's Supreme Court, which is hearing challenges to the voting on fund closures and will decide on distribution of money. This secrecy is indefensible. The public has lost hard-earned savings at a very difficult time. It has a right to know why and how things came to such a sorry pass.

Failures like IL&FS, Yes Bank and Templeton have been absorbed by the Indian financial system, but at a cost. The cracks in confidence have had to be papered over with an abundance of liquidity that poses its own risks to economic stability. It's time regulators took their jobs more seriously.

BLOOMBERG

# Covid vaccine: How to ensure equitable distribution



ATANU BISWAS

One of my acquaintances, a professor at the University of Florida, was reasonably excited when she got the Covid vaccine shot offered by the university fairly quickly. Every country, however, needs its own plan for procurement, distribution and prioritisation for vaccination according to its socio-economic and demographic structure. This is undoubtedly an unprecedented scale of vaccination in India — a much more extensive exercise than the polio vaccination to which we are accustomed for years. "It will be 2024 till everybody gets vaccinated," experts believe. Even if the procedure is expedited in the presence of multiple vaccines, the vaccination procedure would take quite some time to conclude, for sure.

In India, at least the government has already outlined a suitable plan for the initial stages of vaccination — frontline healthcare professionals first, then the frontline workers and people aged above 50 and a special category of those below 50 with comorbidities and requiring specialised care. Certainly, we need equity, not equality, in vaccine distribution, and that is maintained in this plan with some sort of emphasis on the risk factor and also due recognition of the importance of frontline healthcare professionals and frontline workers in the society.

However, how ordering for the healthy people below 50 will be done may not be fixed yet. Will they be vaccinated randomly, or according to their registration chronology, or is there any priority according to their vulnerability? It might not be a bad idea to set an appropriate objective function and carry out the vaccine allocation to them by optimising that objective function.

The Western world's vaccination programme was started with the UK, and a 91-year-old woman was the first to get the vaccine. Interestingly, while most countries have planned to put their vulnerable older people first in line for vaccination, Indonesia planned to vaccinate its young

working-age population before the elderly. They've their own argument for not bucking the trend, of course. One important point is that Indonesia has initial access only to a vaccine developed by China's Sinovac Biotech, which does not have enough data yet of the vaccine's efficacy on elderly people, as the ongoing clinical trials in the country involves people aged 18-59. Fair enough. To achieve "herd immunity", Indonesia planned to immunise 67 per cent of its target 18-59 group, who are more socially mobile and economically active. Such types of targeted inoculation procedures are in contrast to the straight-forward one, ie vaccinating proportionately in different strata (constituted according to age groups and occupations). It's difficult to predict the right



**We need equity, not equality, in vaccine distribution, and that is maintained in India's plan with some sort of emphasis on the risk factor and also due recognition of the importance of frontline workers**

approach though, as nobody knows how the situation will evolve in the coming days. And, in a country like India, the older people, in general, may not always be too less exposed to the risk.

I was reading an interesting research article published in *Nature Medicine* in December (<https://www.nature.com/articles/s41591-020-01191-8>), written by scientists from Johns Hopkins University, University of Maryland and PolicyMap, Inc, Philadelphia, where, in the context of the US, an effective community-level risk-based analysis using some sophisticated statistical modelling was done to identify relatively small fractions of the population (for example 4.3 per cent) that might experience a disproportionately large number of deaths (48.7 per cent). In fact, these authors introduced a web-based Covid-19 mortality risk calculator for the US adult (aged 18

years and older) population and interactive maps for viewing community-level risks. They integrated information from pandemic forecasting models so that an individual's absolute risk can be informed based not only on their underlying risk factors, but also on community-level risk due to underlying pandemic dynamics. A web-based risk calculator (<https://covid19risk-tools.com/riskcalculator>) is available that allows an individual to input information on risk factors and obtain estimates of individualised risk for Covid-19 mortality in numerical values.

I was playing with the model. For example, a 45-year-old, 5'8" tall, black or African-American weighing 180lbs, who never smoked, living in Glen Saint Mary town in Florida, has an estimated 0.26 (95 per cent CI: 0.24-0.28) times the risk of dying from Covid-19 compared to the average risk for the US population. With other conditions kept fixed, the man will have estimated 1.4 times the risk compared to an average American if the age is 60, and the risk will be 7.1 times if the age is 75. If the 45-year-old person is a smoker and has chronic heart disease and (controlled) diabetes, the risk will be 0.69 times the average value, whereas it will be 9.8 times the average value if the age is also increased to 75.

Thus, the first 10 per cent of the (remaining) people to be inoculated can be those having top 10 per cent mortality risk (among the remaining people), according to this calculator; the next 10 per cent maybe the next 10 per cent in terms of mortality risk; and so on. Such a model, however, emphasises on the risk of mortality only. As in the Indonesian case, economic activities may also be of importance in the process of inoculation — specially in the quest to bring normalcy, be that a new normal. Thus, the objective function may consider mortality and economy together, and the risk calculator may also take the economic importance of an individual based on profession. The relative weightages of economic activities and mortality maybe a serious issue which the policy-makers should decide and the model can be rebuilt based on the country's perspective. In fact, a separate model could be constructed for each country — using huge Covid-19-related data, census data and various other healthcare data. And that could certainly provide a real "Big Data moment" for Covid-19.

The writer is Professor of Statistics, Indian Statistical Institute, Kolkata

**Dr.Reddy's**

**NOTICE OF LOSS OF SHARE CERTIFICATES**

Notice is hereby given that the following Share Certificates issued by the Company are reported to have been lost or misplaced and the registered Shareholders/Claimants thereto have applied to the Company for the issue of duplicate share certificates.

S No.	Folio No.	Name of the Shareholder	Certificate No(s).	No. of Shares	Distinctive Nos. From - To
1	G00407	Gogineni Gangadhara Rao	12365 23443	20**	73486995 - 73487014 93850466 - 93850485
2	B02396	Babulal Kanjibhai Tarpara Kusun Babulal Tarpara	211454	10*	26264975 - 26264984
3	K04452	Kusum B Tarpara Babulal K Tarpara	216011	10*	26369256 - 26369265
4	T00080	Tushar R Parekh	18413	264**	76834400 - 76834663
5	Y00095	Y Lakshmi Narayana	192521 192522	100* 100*	19639017 - 19639116 19639117 - 19639216

\*Shares of Rs.10/- face value \*\*Shares of Rs.5/- face value

The public is hereby cautioned against dealing in any manner with the above share certificates. Any person(s) who has/have any claim in respect of the said share certificate(s) should lodge claim(s) at the Company's Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034 within 15 days of publication of this notice after which no claim(s) will be entertained and the Company will proceed to issue share certificate(s) of Rs.5/- face value in lieu of Rs.10/-face value pursuant to subdivision of shares of the Company or issue duplicate share certificate(s) of Rs.5/- face value.

For Dr. Reddy's Laboratories Limited  
Sandeep Poddar  
Company Secretary

Place : Hyderabad  
Date : January 22, 2021

**DR. REDDY'S LABORATORIES LIMITED**  
Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034  
CIN: L85195TG1984PLC004507, Tel: 91 40 4900 2900; Fax: 91 40 4900 2999  
email: shares@dreddys.com; website: www.dreddys.com

**WOCKHARDT LIFE WINS**

**WOCKHARDT LIMITED**  
CIN: L24230MH1999PLC120720  
Regd. Off.: D-4 MIDC, Chikalthana, Aurangabad - 431 006  
Phone: 91-240-669 4444 / Fax: 91-240-248 9219  
Email id: investorrelations@wockhardt.com / Website: www.wockhardt.com

**NOTICE**

NOTICE is hereby given pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that a meeting of the Board of Directors of the Company will be held on 29<sup>th</sup> January, 2021, *inter-alia*, to consider and approve the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended 31<sup>st</sup> December, 2020.

This information is also available on the website of the Company [www.wockhardt.com](http://www.wockhardt.com) and on the website of the Stock Exchanges [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)

For Wockhardt Limited  
Sd/-  
Gajanan Sahu  
Company Secretary

Place: Mumbai  
Date: 21<sup>st</sup> January, 2021

**NOTICE**

**DSP MUTUAL FUND**

NOTICE is hereby given that DSP Trustee Private Limited, the Trustee to DSP Mutual Fund ('Fund'), has vide Resolution dated January 22, 2021, declared dividend in the dividend option of below mentioned schemes of the Fund, the particulars of which are as under:

**Record Date: January 28, 2021**

Scheme(s)/Plans/Options	Quantum of Dividend per unit (Rs.)	Face Value per Unit (Rs.)	NAV as on January 21, 2021 (Rs.)
DSP Top 100 Equity Fund – Regular Plan – Dividend Option	1.05	10.000	21.059
DSP Top 100 Equity Fund – Direct Plan – Dividend Option	1.17	10.000	23.429
DSP Equity & Bond Fund – Regular Plan – Dividend Option	0.15	10.000	24.392
DSP Equity & Bond Fund – Direct Plan – Dividend Option	0.15	10.000	46.577
DSP US Flexible* Equity Fund – Regular Plan - Dividend Option	2.32	10.000	23.2355

\*The term "Flexible" in the name of the Scheme signifies that the Investment Manager of the Underlying Fund can invest either in growth or value investment characteristic securities placing an emphasis as the market outlook warrants.

Distribution of the above dividend is subject to the availability and adequacy of distributable surplus.

**Pursuant to payment of dividend, the NAV of the Dividend Option(s) under Regular and Direct plans of the aforesaid schemes of the Fund would fall to the extent of payout and statutory levy, if any.**

Dividend will be paid to all those Unit Holders / Beneficial Owners, in the Dividend Option (s) of Regular and Direct plan of the aforesaid schemes of the Fund, whose names appear in the records of the Registrar and Transfer Agent, Computer Age Management Services Limited / statement of Beneficiary Owners maintained by the Depositories as on the Record Date. The payout shall be subject to tax deducted at source (TDS) as applicable.

Unit holders are advised to update any change of address / bank details, if any, with depository participant(s) in advance of the Record Date.

Any queries/clarifications in this regard may be addressed to:  
**DSP Investment Managers Private Limited ("AMC")**,  
CIN: U74140MH1996PTC099483,  
Investment Manager for DSP Mutual Fund,  
Mafatall Centre, 10th Floor, Nariman Point, Mumbai 400 021  
Tel. No.: 91-22 66578000, Fax No.: 91-22 66578181,  
Toll Free No: 1800 200 4499, www.dspim.com

**Investors/unit holders are requested to update their email address and mobile number with the AMC.**

Place: Mumbai  
Date: January 22, 2021

**Mutual Fund investments are subject to market risks, read all scheme related documents carefully.**

